hrp0095p2-67 | Diabetes and Insulin | ESPE2022

Impact on metabolic control in pediatric patients with use of technology applied to type 1 diabetes

Gil Poch Estela , Babiano Benito Lucía , Javier Arroyo Díez Francisco

Background and Aims: The treatment of type 1 diabetes (T1D) requires a great involvement of the patient to achieve optimal blood glucose levels. Technological devices have been developed for individualized treatment, fewer interventions of the patient, and evidence of improved metabolic control. The aim of the study is to know data on metabolic control in a group of pediatric patients with T1D treated with new technologies, compared to patients treated with mu...

hrp0092p3-306 | Late Breaking Abstracts | ESPE2019

Improvement of Metabolic Control in Children with Type1 Diabetes Using Continuous Glucose Monitoring Devices

Gil-Poch Estela , Roco-Rosa María , Javier Arroyo-Díez Francisco

Introduction: Achieving metabolic control in children with type 1 diabetes (T1DM) is not an easy task. Despite the new profiles of insulins and therapies with continuous infusion, hypoglycemia continue to be the most important barrier that prevents us from correctly controlling these patients.Close control of capillary glycaemia is important for treatment adjustment. This self-control provides us with static information about capillary g...

hrp0089p3-p407 | Diabetes & Insulin P3 | ESPE2018

Degludec Versus Glargine in Pediatric and Adolescent Patients with Type 1 Diabetes

Gil-Poch Estela , Javier Arroyo-Diez Francisco , Beato-Vibora Pilar I

Introduction: To optimal glycemic control without hypoglycemia must be the aim of insulin treatment for all patients with type 1 diabetes (T1DM). Despite the advantages of the basal-bolus insulin regimens with MDI, hypoglycemia presents a major barrier in achieving desirable blood glucose levels. Degludec is a new basal insulin analog with longer half-life and lower variability.Objetive: To investigate the differences between long-acting insulins glargin...

hrp0086p2-p285 | Diabetes P2 | ESPE2016

Permanent Neonatal Diabetes by Gene Mutation KCNJ11. Evolution and Treatment after Three Years with Sulphonylureas

Angeles Santos Mata Maria , Fernandez Viseras Irene , Torres Barea Isabel , Jose Macias Lopez Francisco , Catano Luis

Background: Permanent neonatal diabetes (PND)with heterozygous mutations of KCNJ11, respond to treatment with sulphonylureas. We report a case of PND in a baby, and mother previously mis-diagnosed with Type 1 DM. Both were switched from insulin to oral sulphonylureas. We evaluate the response and evolution.Case report: A male newborn at 37 weeks’ gestation, with a birthweight 2750 g (40thC) and length 48 cm (40thC), was admitte...

hrp0086p2-p524 | Fat Metabolism and Obesity P2 | ESPE2016

Non-Alcoholic Hepatic Steatosis in Obese Children and the Relationship with Insulin Resistance

Fernandez Viseras Irene , Angeles Santos Mata Maria , Jose Macias Lopez Francisco

Background: Hepatic steatosis is common in obese children. The pathophysiology remains unexplained but it is known that insulin resistance and hypertrilycerdemia are involved in its development.Objective and hypotheses: To analyse the prevalence of hepatic steatosis identified by ultrasound, as well as features and anthropometric data in our population divided into two groups: (with steatosis and without steatosis) to assess the risk factors.<p class...

hrp0082p2-d1-452 | Growth | ESPE2014

Rasopathies: Assessment of Growth, Genetic Study, Genotype–Phenotype Correlation and Therapeutic Response to GH in Noonan Syndrome

Heredia Claudia , Barros Francisco , Castro-Feijoo Lidia , Conde Jesus Barreiro , Rodriguez Paloma Cabanas , Arias Manuel Pombo

Background: Rasopathies are a heterogeneous group of diseases that share phenotypic characteristics such as facial dysmorphism, congenital heart disease and short stature.Objective and hypotheses: Evaluation of growth and study of the GH–IGF1 axis. Molecular Study of the PTPN11, SOS1, RAF, KRAS, NRAS, MAP2K1 and MAP2K2 genes. Evaluation of growth and study of the GH–IGF1 axis.Method: Descriptive retrospective study in pat...

hrp0094p2-362 | Pituitary, neuroendocrinology and puberty | ESPE2021

Congenital hypopituitarism: the role of genetics

Gil Poch Estela , Javier Arroyo Diez Francisco , Mendez Perez Pilar , Galan Gomez Enrique ,

Hypopituitarism refers to the insufficient secretion of one or more pituitary hormones. If default is present at the time of birth is called congenital hypopituitarism (CH). Causes of this are perinatal pathology and genetic alterations. The clinical presentation is heterogeneous. The diagnosis is made by clinical suspicion supported by hormonal determinations, brain imaging test (MRI) searching of structural defects and genetic study. The development of the pituitary gland is...

hrp0097p1-440 | Diabetes and Insulin | ESPE2023

Monogenic forms of neonatal diabetes: our casuistics and evolution

Ángeles Santos Mata María , Pacheco Carrillo Aitana , Ruiz Ocaña Pablo , Macías López Francisco

Neonatal diabetes (ND) occurs in 1/100,000-150,000 newborns with hyperglycemia in the first six months of life, requiring insulin treatment for at least two weeks, with no autoimmune basis. Two forms are described, transitory (TND) and permanent (PND). In 50% cases of TND, remission presents within the first year of life, only to relapse later before puberty in 50% of cases.CASE 1: Newborn with sustained hyperglycemia since the third day of life, requiri...

hrp0097p2-28 | Pituitary, Neuroendocrinology and Puberty | ESPE2023

Hipothalamic syndrome in craniopharyngioma: pre and post-surgery

Coelho Isabel , Francisco Branco Caetano , Iraneta Amets , Conceição Carla , Lopes Lurdes , Galhardo Júlia

Introduction: Craniopharyngioma (CP) is a histologically benign rare tumor from the sellar and parasellar region. Its invasion into adjacent structures, namely optic nerve and hypothalamic-pituitary axis brings significant morbidity and warrants surgical treatment. Hypothalamic Syndrome (HS) can occur in different conditions affecting this structure, comprising a cluster of symptoms like pituitary dysfunction, obesity, temperature dysregulation, sleep disturba...

hrp0095fc9.2 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Can pre-treatment BMI influence long-term anthropometric and metabolic outcomes in girls with idiopathic central precocious puberty treated with GnRHa?

Bruzzi Patrizia , Sandoni Marcello , Valeri Lara , Trevisani Viola , Dalla Porta Francesca , Filomena Madeo Simona , Lucaccioni Laura , Predieri Barbara , Iughetti Lorenzo

Background: Gonadotropin releasing hormone analogs (GnRHa) are effective in improving adult height in children with precocious onset of puberty, rapid progression, and good growth potential. In last years, however, some transient metabolic complications have been described during the treatment without the reassurance of long-term data yet. The aim of our study is to clarify if body mass index (BMI) at diagnosis of idiopathic central precocious puberty (iCPP) c...